15 citations
,
October 2022 in “Allergy” Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.
53 citations
,
January 2018 in “JAAD case reports” Dupilumab for eczema may cause hair loss.
1 citations
,
October 2022 in “Rheumatology” RHUPUS should be considered in children with deforming arthritis.
5 citations
,
February 2021 in “Gels” HYDRO DELUXE BIO hyaluronic acid hydrogel is compatible with skin cells, may reduce inflammation, promote blood vessel growth, and protect against oxidative stress, suggesting it could help revitalize hair follicles.
May 2025 in “Galen Medical Journal” New targeted therapies for psoriasis show promise but face challenges like side effects and treatment resistance.
1 citations
,
August 2024 in “SAR Journal of Pathology and Microbiology” Many Iraqi women with hirsutism also have hypothyroidism and acne.
January 2026 in “Dermatology Reports” Upadacitinib improved symptoms and hair regrowth in a teen with multiple autoimmune conditions.
October 2022 in “Portuguese journal of dermatology and venereology” Dupilumab led to complete hair regrowth and improved skin condition in a young man with severe eczema and hair loss.
77 citations
,
April 2016 in “British journal of dermatology/British journal of dermatology, Supplement” IL-17 is a key target for treating inflammatory skin diseases, especially psoriasis.
1 citations
,
March 2023 in “Journal of Drugs in Dermatology” Dupilumab may help regrow hair in people with severe alopecia.
24 citations
,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
11 citations
,
June 2023 in “Drug Delivery and Translational Research” The gel with apocynin-loaded nanoparticles shows promise for treating rheumatoid arthritis.
23 citations
,
January 2012 in “International Food Research Journal” Tofacitinib effectively treated a woman's severe symptoms from a rare autoimmune condition.
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
Combining baricitinib with golimumab helped regrow hair in a patient with ankylosing spondylitis and alopecia areata.
15 citations
,
January 2006 in “British Journal of Dermatology” A woman with skin eruptions and hair loss improved significantly with ointment treatment.
10 citations
,
August 2019 in “European Journal of Dermatology” The document did not conclude on apremilast's effectiveness for severe alopecia areata.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Abatacept may help some people with alopecia areata regrow hair.
Betamethasone is more effective long-term for alopecia areata than hydroxychloroquine.
1 citations
,
September 2025 in “JAAD reviews.” Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
April 2017 in “Journal of Investigative Dermatology” SIG-1451 could be a promising new treatment for atopic dermatitis.
January 2026 in “Skin Health and Disease” Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
November 2024 in “Journal of Investigative Dermatology” Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.
1 citations
,
September 2024 in “Dermatological Reviews” Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.
February 2016 in “Annals of the Rheumatic Diseases” All four treatments for early rheumatoid arthritis had similar and mostly mild side effects.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
7 citations
,
January 1993 in “Rheumatology” Most skin rashes in rheumatoid arthritis patients were not caused by their medication, and careful evaluation allowed most to keep taking their beneficial treatment.
February 2024 in “PloS one” Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.